Neuropeptide Y in the Medial Prefrontal Cortex Modulates Ethanol Consumption in Mice by Perez-Heydrich, Carlos et al.
 Neuropeptide Y in the Medial Prefrontal Cortex Modulates 
Ethanol Consumption in Mice 
Carlos A. Perez-Heydrich, Stacey Robinson and Todd E. Thiele 
Behavioral and Integrative Neuroscience, Department of Psychology and Neuroscience & Bowles Center for 
Alcohol Studies, UNC-Chapel Hill, 27599 
 
Binge-like drinking behavior has been estimated to cause about 80,000 deaths in the United States 
annually and is a significant risk factor for developing ethanol dependence. This behavior is partially 
regulated by control of the amygdala by the medial prefrontal cortex (mPFC). A neurotransmitter called 
neuropeptide Y (NPY) binds to neurons in the mPFC projecting to the amygdala, thus we hypothesized that 
NPY regulates binge-like drinking behavior. In the mPFC, NPY has a post-synaptic receptor NPY1R, and 
a presynaptic receptor NPY2R. To test NPY’s affect in modulating ethanol intake, we pharmacologically 
agonized NPY1R and pharmacologically antagonized NPY2R. The agonism of NPY’s post-synaptic 
receptor and the antagonism of NPY’s presynaptic receptor both resulted in reduced ethanol intake 
compared to vehicle treated animals.  To further study NPY’s role, we chemogenetically inhibited neurons 
in the mPFC expressing NPY1R through the use of a Designer Receptor Exclusively Activated by a 
Designer Drug (DREADD). This specific inhibition of NPY1R expressing cells in the mPFC resulted in 
decreased consumption of ethanol. To examine the effects of binge-like drinking on NPY activity in the 
mPFC, we performed immunohistochemistry and found a decrease in NPY immunoreactivity after three 
weeks of binge-like drinking.  These results establish a role for NPY modulation of binge-like drinking 
behavior in mice. This study could help understand how people develop alcohol dependence and suggest 
therapeutic strategies.  
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 Neuropeptide Y’s Role in Modulating Ethanol Consumption in the Medial Prefrontal Cortex in Mice 
Introduction: 
Binge-like drinking behavior is estimated to have led to about 80,000 deaths in the United States 
annually and is a significant risk factor for developing an ethanol dependence (NIAAA. 2016; Kanny, D, 
2012). Previous research has identified three major elements of addiction (Koob, George Fv. 2015; Volkow, 
N. D., Koob, G. F., & McLellan, A. T. 2016). The first element of the addiction model is a decrease in the 
reward feedback due to the substance, where the substance does not offer the same stimulation as it 
originally did. The next element is an increase in the number of and intensity of behavioral and physical 
responses a person has to the substance. The last characteristic is that the regions of the brain that regulate 
decision-making are damaged due to continual exposure to the substance (Volkow, N. D., Koob, G. F., & 
McLellan, A. T. 2016;). This cycle of development and maintenance of an addiction are still being studied.  
A notable effect of alcohol use is alcohol's ability to decrease anxiety and stress, which has been 
noted to be a factor in the development of addiction following long-term use (Frone, Michael R. Work. 
2016). Due to alcohol’s role in decreasing stress, the brain regions associated with modulating emotion are 
areas of interest to examine the effects of alcohol on the brain. One such center is the amygdala which is a 
regulator of mood and emotion in the limbic system (Lalumiere RT. 2014; Pleil KE, Lowery-Gionta EG, 
Crowley NA, Li C, Marcinkiewcz CA, Rose JH, et al..2015). One pathway of interest is the possible top-
down regulation of the amygdala by the medial prefrontal cortex (mPFC). The mPFC has been shown to 
be a site of executive functioning and a regulator of reward seeking behavior (Ramnani, Clare. Stephen M 
Smith.2004). The mPFC is subdivided into the more ventral infralimbic region (IL) and more dorsally 
located prelimbic region (PL) (Lalumiere RT 2014). The IL region has been shown to regulate behavior 
associated with habitual-oriented behavior, while the PL region of the mPFC has been associated with goal-
oriented behavior (Vertes RP 2004). Also, both of these regions are known to have projections that innervate 
the basolateral amygdala (BLA) (Barker, J. M., Taylor, J. R., & Chandler, L. J. 2014; Carballedo A, Möller 
HJ, et al. 2011). The BLA is a critical regulator of the extended amygdala (EA), which is associated with 
 emotional behavior as well as a driver of alcohol consumption (Lowery-Gionta, E., Navarro, M., Li, C., 
Pleil, K., Rinker, J., & Cox, B. et al. 2012). Due to the mPFC’s position to regulate the amygdala’s activity, 
and therefore anxiety and stress-related behaviors, the mPFC is of great interest when studying brains 
regions associated with the development of ethanol dependence.   
Within the mPFC, a subpopulation of the primary inhibitory GABAergic interneurons express 
neuropeptide Y (NPY) (Kubota Y, Shigematsu N, Karube F, Sekigawa A, Kato S, Yamaguchi N, et al. 
2011; Lalumiere RT. 2014). NPY is a 36 amino acid polypeptide chain that is part of the neuropeptide 
tyrosine family (Allen, Y. S., Bloom, S. R., & Polak, J. M. 1986). NPY could be an important modulator 
of ethanol dependence due to its role as an anti-stress neurotransmitter (Allen, Y. S., Bloom, S. R., & Polak, 
J. M. 1986; Robinson, Stacey L., & Thiele, Todd E. 2017). NPY is a signaling molecule that binds to a G 
protein-coupled receptor that causes a signal cascade within cells and inhibits the postsynaptic neuron from 
firing (Thiele. 2017). The GABAergic interneurons that release NPY modulate the mPFC’s excitatory 
glutamatergic projection neurons and local inhibitory GABAergic signaling (Klein CR, et al. 2013).  The 
NPY system includes a post-synaptic receptor NPY1R on glutamatergic and GABAergic neurons and a 
mostly pre-synaptic homo- and heteroreceptor NPY2R that is expressed on the GABAergic interneurons 
(Palmiter RD et al. 1998; Sparrow AM 2012). As a homoreceptor, NPY2R has also been implicated as a 
possible reuptake channel for NPY, so it’s activation could affect the amount of NPY in the synaptic cleft, 
therefore indirectly affecting NPY1R signaling (Sparrow AM 2012).  
One transgenic decreased NPY expression, which then led to increased ethanol consumption and, 
conversely, an over-expression of the NPY gene led to decreased ethanol consumption (Thiele TE, Palmiter 
RD. 1998). This earlier method of ubiquitously over-expressing NPY via transgenic means provided 
evidence of NPY’s ability to modulate ethanol consumption, but this method did not isolate where in the 
brain NPY is able to target. Part of this study’s goal is to target one of NPY’s sites of modulation to the 
mPFC.  
Due to NPY’s position to influence ethanol intake, an in-depth analysis of NPY’s role could offer 
insights into the biological changes that take place in the brain that lead to the transition to ethanol 
 dependence. The role of NPY in regulating the mPFC’s projections to the amygdala has yet to be evaluated. 
Based on the previous research implicating NPY as a modulator of binge-like ethanol consumption, it was 
predicted that increasing NPY signaling in the mPFC will decrease binge-like ethanol consumption. In this 
study, the NPY signaling was studied through the use of pharmacological excitation of NPY’s postsynaptic 
receptor and inhibition of NPY’s presynaptic receptor. Furthermore, NPY1R expressing (NPY1R+) cells 
in the mPFC were chemogenetically inhibited to provide further evidence of NPY’s integral role in the 
development of alcohol addiction. Along with these interventional experiments, the change in 
immunoreactivity of NPY in the mPFC was measured after binge-like exposure to ethanol. To model binge-
like ethanol consumption in mice in all three experiments, the “Drinking in the Dark” (DID) method was 
used in this project. DID has been shown to be a useful tool in modeling binge-drinking behavior in mice, 
which can then be used to determine if a treatment process will alter an animal’s drinking pattern (Thiele 
TE, Crabbe JC, Boehm SL 2014; Sparrow GM, Thiele TE 2012). This analysis of NPY’s role in ethanol 
dependence could help understand how people transition to alcohol dependence and provide targets for 
therapeutics.  
 
 
 
 
 
 
 
 
  
 
 
 Methods: 
Animals: 
For the immunohistochemistry and pharmacological experiments, male and female C57BL/6J mice 
(Jackson Laboratories, Bar Harbor, ME) were obtained at about 6-8 weeks of age. For the chemogenetic 
studies NPY1R-Cre mice (positive for Cre-recombinase under the NPY1R promoter, determined by 
standard polymerase chain reaction genotyping) on a C57BL/6J background >10 weeks old at experiment 
start. The animals were housed individually in plastic containers in a room that was approximately 22°C 
and were given a week to acclimate before trials. The mice were maintained on an alternating light-dark 
cycle of 12 hours of darkness starting at 8am and 12 hours of light starting at 8pm. The mice had access to 
Prolab® RMH 3000 (Purina LabDiet®; St. Louis, MO) and water, unless otherwise stated in experiments. 
All procedures used in this study are in accordance with the National Institute of Health guidelines, and 
were approved by the University of North Carolina Institution Animal Care and Use Committee. 
  
“Drinking in Dark” Procedures 
The DID method has been used to obtain high levels of ethanol consumption in mice (Thiele TE, 
Crabbe JC, Boehm SL.2012). The DID procedure was done over a 4-day period. On the first 3 days, the 
animals’ waters were removed from their cages and they were given access to ethanol for 2-hour periods, 
3.5 hours into their dark cycle. On the 4th day, the animals were given their drug treatment (described below) 
30 minutes prior to their trial and then the animals’ water bottles were switched from water to ethanol. The 
trials ran for 2 hours. For the immunohistochemistry experiments, the animals underwent three cycles of 
DID. For the pharmacological and chemogenetic studies, the animals underwent 2 cycles of DID with 
ethanol followed by 2 cycles of DID where sucrose (3%) took the place of ethanol in each part of the 
procedure. Sucrose trials are an effective control experiment because sucrose has a caloric value and is 
rewarding to mice, similar to ethanol. See Figure 1a for the DID procedure for the IHC experiments and 
 Figure 2a for the pharmacological and chemogenetic experiments. In pharmacological and chemogenetic 
studies tail blood samples (≈60µL) were taken immediately following DID procedure to determine BECs 
using the AM1 Alcohol Analyzer (Analox, London, UK). 
  
Surgery 
Before surgery, the mice were anesthetized with a mixture of xylazine (10mg/kg) and ketamine 
(100mg/kg) via I.P injection. For the mice in the pharmacological studies, a bilateral 26-guide cannulae 
was implanted in the mice’s mPFC (AP: 1.7, ML: ±0.4, DV: −2.6) or BLA (AP: -1.22, ML: ±3.01, DV: 
−4.75) with an Angle II™ Stereotax (Leica Instruments, Buffalo Grove, IL) and the help of stereotaxic 
atlas. For the mice that were used in the chemogenetic studies, the mPFC was injected with 0.3-0.5 µL/side 
(over a 3-5 minute period) of either a Cre-dependent control vector (CON DREADD; AAV8-hSyn-DIO-
mCherry) or the Cre-dependent Gi coupled Designer Drug Exclusive Activated by Designer Drug 
(DREADD) vector (Gi-DREADD; AAV8-hSyn-DIO-hM4d-mCherry (UNC vector core, North Carolina)).  
The injection needle remained in place for 10-15 additional minutes before being withdrawn. Mice 
recovered for >3 weeks before being used for experiments.  
  
Drug Administration 
On the DID test days for the mice, the animals in the pharmacological studies either received their 
respective vehicle or drug (NPY1R agonist Leu, Pro-NPY (99 pmol/0.5µl/side) or NPY2R antagonist 
BIIE0246 (3µg/0.5µl/side) (Tocris, Minneapolis, MN)) 30 minutes before the experiment.  The drugs were 
administered to the mPFC cannulae at a rate of 0.3uL/min via a Hamilton syringe (Reno, NV) attached to 
a Harvard Apparatus PHD 2000 infusion pump (Holliston, MS). After the infusion, the injectors were kept 
in place for 0.5-1 minute to allow for diffusion of the drug. These trials were done with a Latin-square 
design where the mice were randomly assigned to receive either the drug or the vehicle on the first test day 
of a DID cycle and then on the second DID cycle test day the animal would receive the alternate treatment 
 (See Fig. 2a for diagram). Comparing the change in ethanol intake for each mouse following drug treatment 
to the vehicle treatment allows each mouse to act as their own control. Also, by randomly assigning animals 
to treatment groups, there were groups of mice that underwent drug treatment first followed by vehicle 
treatment, and vice versa.  
The animals in the chemogenetic studies either received Clozapine-N-Oxide (CNO; intraperitoneal 
(I.P.) 3.0 mg/kg; microinjection to BLA 900 pmol/0.3µl/side; Sigma-Aldrich, St. Louis, MO; in 0.5% 
DMSO + Saline) or vehicle via an I.P. injection or microinjection to the BLA. These trials were also done 
using a Latin-square design. 
 
Perfusion of Mice and Brain Slide Preparation 
Mice were sacrificed with a ketamine overdose and were transcardially perfused with phosphate 
buffered (0.1M) saline directly followed by paraformaldehyde (4%). The brains were extracted and 
preserved in paraformaldehyde (4%) for 24 hours and then the brains were sliced using a vibrating 
microtome (Leica VT1000S; Wetzlar, Germany). The slices for the pharmacological and chemogenetic 
studies were mounted on slides for inspection of cannulae placement with an optical microscope (BX-51, 
Olympus). Any animals whose cannulae were misplaced were excluded from the study. 
  
Immunohistochemistry 
Mice used for immunohistochemistry went through three cycles of DID with ethanol, or three 
cycles of water DID. In the ethanol trials, after the last cycle of DID, blood samples were collected for 
blood ethanol concentration (BEC) analysis. Mice then went through the same perfusion and brain slicing 
procedure described in Perfusion of Mice and Brain Slide Preparation section. The slices of brain were then 
incubated in citrate buffer at 66°C for 1 hour for antigen retrieval and then used for NPY immunoreactivity 
detection. The slices were incubated in a 1° anti-NPY (1:1000) (produce/specified verified by ABcam, 
Cambridge, United Kingdom) for 72 hours. The slices were then incubated in a secondary solution for 2 
 hours (DyLight 488, 1:5000, Vector Laboratories, Burlingame, CA), and mounted on glass slides. The brain 
slices were then imaged via a digital camera (Roper Scientific), mounted on an optical microscope (BX-51, 
Olympus), and the amount of fluorescence was quantified using ImageI (NIH). 
 
Open Test and Anxiety Like Behavior 
A week after the animals in the pharmacological and chemogenetic studies completed the trials 
where they were exposed to sucrose, mice underwent behavioral testing (three weeks after DID ethanol or 
water testing). Animals were randomly assigned into either drug or vehicle groups in a similar manner as 
in the DID testing. The tests began 4-6 hours into the dark cycle of the mice. The possible change in 
locomotor activity due to treatments was observed by VersaMax® software program (AccuScan 
Instruments, Inc., Columbus, OH) (dimensions: 16.5 x 16.5 x 12 inches) over 2h period with five minute 
bin outputs. Time spent in the chamber center during the first five minutes of the trial period was recorded 
to determine any effects on anxiety-like behavior. Time spent in the center of the chamber is meant to 
measure the willingness the animal is to be exposed in a non-covered area, so measuring that time in the 
chamber provides a numerical value for anxiety-like behavior (Prut L, Belzung C. 2003).  
 
Statistical Analysis 
GraphPad Prism (GraphPad Software, Inc. La Jolla, Ca) was used to analyze and graph all data, 
save three-way ANOVAs which were performed in SPSS statistics (IBM Analytics, Armonk, New York). 
Two-way ANOVAs and Bonferroni post-hoc tests were used to determine the effect of binge cycle on NPY 
immunoreactivity and treatment versus time during individual DID drinking hours. T-tests were used to 
evaluate effect of treatment on total intake and BEC. All data are reported as the mean ± standard error of 
the mean and considered significant if p<0.05. Animals were removed from analysis if they were found to 
be a significant outlier as detected by a Grubbs test (Alpha=0.05) or cannulae misplacement (unilateral or 
bilateral) or inappropriate (lack of/incorrectly placed) DREADD expression was found. Cannula placement 
 was determined by locating the end of the guide cannulae and adding injector projection length (2MM in 
mPFC and 0.5MM in BLA). Three-way ANOVA analysis found no significant effect of treatment order in 
any Latin-square design experiment, therefore these data were collapsed and analyzed by two-way 
ANOVA. Two-way ANOVA found no significant effect of sex on any data set, therefore data from males 
and females were collapsed. 
 
Results: 
Three Cycles of binge-like ethanol intake decreased PL NPY immunoreactivity, but 
did not change IL NPY immunoreactivity 
The model for addiction notes there are changes that take place in the brain as an organism begins 
to become dependent on ethanol, but the mechanisms by which the brain’s biochemistry changes are not 
completely known. The following experiment looked to examine the changes in NPY expression that would 
take place in the early stages of binge-like ethanol consumption. To determine the change in NPY 
immunoreactivity one cohort of mice (N=12) went through 3 round of DID and another cohort of mice 
(N=10) went through water exposure. A two-way ANOVA test revealed a significant change in NPY 
immunoreactivity due to ethanol exposure [F(1,20)=4.422, p<0.05], but not mPFC subregion 
[F(1,20)=3.613., p>0.05; interaction: F(1,20)=0.458, p>0.05] [Fig. 1b, 1c] on NPY expression. NPY 
expression was found to be significantly correlated with ethanol intake in the prelimbic (PL) [r=0.623, 
p<0.05] [Fig. 1d], but not in the infralimbic (IL) [r=0.301, p>0.05] [Fig. 1e] subregion. NPY expression 
was not found to correlate with water intake in either the PL [r=0.163, p>0.05] [Fig. 1f] or IL [r=-0.52, 
p>0.05] [Fig. 1g]. 
 
  
 
  
NPY1R Agonism in the mPFC Selectively Decreases Binge-Like Ethanol Intake 
NPY has been implicated as a possible modulator of binge-like drinking due to its role as an anti-
stress neuropeptide (Robinson, Stacey L., & Thiele, Todd E. 2017). Pharmacologically activating NPY1R 
in the mPFC would mimic the presence of NPY in the synaptic cleft and was expected to reduce ethanol 
consumption in mice. An ANOVA test evaluating time and cranial microinjection of NPY1R agonist Leu 
Pro-NPY showed significantly reduced ethanol consumption compared to vehicle treatment (N=21) 
[Treatment: F(1,20)=10.62, p<0.01; Time: F(1,20)=0.997, p>0.05; interaction: F(1,20)=0.053, p>0.05; 
Total t-test: t=3.259 df=20, p<.01] [Fig. 2b]. There was a significant reduction in the blood ethanol 
concentration (BEC) of drug treated animals compared to vehicle treated animals (N=18) [t=2.223 df=17, 
p>0.05] [Fig. 2c]. This was a specific interest because the BEC of drug treated animals where below 80 
mg/dl, which is the National Institute of Alcohol Abuse and Alcoholism (NIAAA) standard for what is 
considered a binge of ethanol consumption (represented as dashed line) (NIAAA. 2016; Kanny, D, 2012). 
A caloric reinforcing liquid- sucrose (3%)- was used to determine if NPY1R agonist activity was specific 
to ethanol consumption or other rewarding stimuli. Two-way ANOVA test did not find a significant change 
in sucrose consumption between drug treated animals and vehicle treated animals (N=14) [Treatment: 
F(1,13)=0.0128, p>0.05; Time: F(1,13)=0.29, p>0.05; interaction: F(1,13)=2.367, p>0.05] [Fig. 2.d]. Mice 
that had cannula placements outside of the mPFC region were excluded from the study [Fig.2.e]. 
To examine the effect of Leu Pro-NPY on locomotor activity, an open-field test tracking the mice’s 
total distance travelled over a 2-hour period was performed. This experiment showed no significant change 
in locomotor activity of the mice due to Leu Pro-NPY at this dosage [Two-way ANOVA: time = F(23, 
253)=40.12, p<0.0001; treatment = F(1, 11)=1.238, p>0.05; interaction: F(23,253)=0.674, p>0.05; Vehicle 
N=8, Leu, Pro-NPY N=5] [Fig 3.a]. The locomotor activity of the animal tested whether the change in 
decrease in ethanol consumption was due to a decrease in overall movement of the animal. To examine the 
effect of Leu Pro-NPY on anxiety-like behavior, the first 5 minutes of the animals in the open-field chamber 
 was examined. Time spent in the center of the open field chamber during the early test period is a generally 
accepted measure of anxiety-like behavior in rodents (Prut L, Belzung C. 2003). There was not a significant 
decrease in anxiety-like behavior in mice at this dose of Leu Pro-NPY (t=0.9389 df=11, p>0.05; Vehicle 
N=8; Leu, Pro-NPY N=5)[Fig.3.b]. 
 
NPY2R Antagonism in the mPFC Selectively Decreases Binge-Like Ethanol Intake 
To further examine NPY’s role of developing binge-like ethanol behavior, pharmacological 
inhibition of NPY’s presynaptic receptor, NPY2R, was examined. NPY2R has been implicated as an 
important modulator of the amount of released NPY in the synaptic cleft (Sparrow AM 2012).  A two-way 
ANOVA test was used to evaluate time and microinjection of NPY2R antagonist BIIE0246 and found 
significant reduction in ethanol consumption compared to vehicle treated animals (N=14) [Treatment: 
F(1,13)=7.639, p<0.05; Time: F(1,13)=3.3531, p>0.05; interaction: F(1,13)=3.224, p>0.05; Total t-test: 
t=2.87 df=13, p<0.05] [Fig. 4a]. There was a corresponding significant decrease in the BEC of drug treated 
animals compared to vehicle treated animals (N=10) (4 blood samples lost due to mechanical error) 
[t=2.921 df=9, p<0.05] [Fig. 4b]. The decrease in BEC was also below the threshold for what is considered 
a binge of ethanol consumption. Sucrose (3%) trials were once again used to determine if drug treatment 
was selectively decreasing ethanol intake or had an effect on other reinforcing substances. Two-way 
ANOVA test evaluating time and treatment did not find a significant change in sucrose consumption 
between drug treated animals and vehicle treated animals (N=14) [Treatment: F(1,12)=0.979, p>0.05; 
Time: F(1,12)=4.338, p>0.05; interaction: F(1,12)=0.125, p>0.05; Total t-test: t=0.9898 df=12, p>0.05] 
[Fig.4c]. Mice that had cannula placements outside of the mPFC region were excluded from the study 
[Fig.4.d]. 
To examine the effect of the NPY2R agonist BIIE0246 on locomotor activity, an open-field test 
tracking the mice’s total distance travelled over a 2-hour period was performed. This experiment showed 
no significant change in locomotor activity of the mice due to BIIE0246 at this dose [Two-way ANOVA: 
 time = F(23,299)=26.97, p<0.0001; treatment = F(1,13)=0.2791, p>0.05; interaction: F(23,299)=0.7306, 
p>0.05; Vehicle N=10, BIIE0246 N=5][Fig.5.a). To examine the effect of BIIE0246 on anxiety-like 
behavior, the first 5 minutes of the animals in the open-field chamber was examined. There was not a 
significant decrease in anxiety-like behavior in mice at this dose of BIIE0246 (t=0.5788 df=13, p>0.05; 
Vehicle N=10; BIIE0246 N=5) (Fig.5.b). 
 
 
Chemogenetic inhibition of mPFC NPY1R neurons decreased binge-like ethanol 
consumption  
NPY binding to NPY1R (a Gi/o-coupled receptor) generates an inhibitory postsynaptic potential, 
and so chemogenetically inhibiting through a Gi-coupled DREADD NPY1R+ cells in the mPFC was a 
direct way to target neurons expressing NPY1R and mimic the effect caused by NPY (Anthony N. van den 
Pol. 2012). In NPY1R-cre mice, mPFC neurons that were injected by the DREADD virus expressed Gi-
coupled DREADDS. These receptors were chemogenetically inhibited via an I.P CNO injection. CNO 
treatment significantly reduced binge-like ethanol consumption compared to vehicle treatment after 2 hours 
of ethanol exposure and this was analyzed using two-way ANOVA (treatment vs. time) (N=12) [treatment: 
F(1,11)=6.684, p<0.05; time: F(1,11)=0.004, p>0.05; interaction: F(1,11)=2.114, p>0.05; Total t-test: 
t=2.585 df=11, p<0.05] [Fig. 6a]. There was not a significant decrease in BEC between CNO and vehicle 
treatment expressing Gi-coupled DREADDS in NPY1R+ mPFC cells (N=10) (2 blood samples lost due to 
mechanical error) [t=1.546 df=9, p>0.05] [Fig.6b]. There was also no significant change in consumption 
of 3% sucrose solution [treatment: F(1,9)=0.123, p>0.05; time: F(1,9)=6.028, p<0.05; interaction: 
F(1,9)=0.003, p>0.05] [Fig. 6c].  
To verify that there were no off-target effects of CNO administration on the mice’s ethanol 
consumption mice were injected with a control (CON) DREADD virus in the mPFC and run through the 
same procedure previously described. These CON DREADD treated animals would not express a receptor 
 that CNO would bind to when administered. These mice were not found to have a significant impact on 
ethanol consumption after administration of CNO using ANOVA analysis (N=9) [treatment: 
F(1,8)=0.0916, p>0.05; time: F(1,8)=1.326, p>0.05; interaction: F(1,8)=0.2158, p>0.05; Total t-test 
t=0.3027 df=8, p>0.05][Fig.6d]. The CON DREADD animals also did not show a significant change in 
BEC after an administration of CNO [t-test t=0.3153 df=8, p>0.05] [data not shown]. The CON DREADD 
animals also did not show a significant change in intake of 3% sucrose solution after an administration of 
CNO (N=9) [treatment: F(1,8)=1.142, p>0.05; time: F(1,8)=1.032, p>0.05; interaction: F(1,8)=0.495, 
p>0.05; Total t-test t=1.069 df=8 p>0.05] [Fig. 6e]. Brains that did not have expression of DREADD 
receptors (tagged in red) were excluded from the study [Fig. 6f]. 
Chemogenetic inhibition of NPY1R+ mPFC-BLA projection neurons decreased 
binge-like ethanol consumption  
The mPFC’s top-down regulation of the amygdala was specifically investigated by performing a 
similar chemogenetic inhibition used above, with an injection of Gi-DREADD or CON-DREADD for the 
respective trials. In the NPY1R-cre mice, mPFC neurons projecting to the BLA expressing CON or Gi 
DREADDS were chemogenetically inhibited via a BLA microinjection of CNO. The administration of 
CNO directly to the BLA is expected to specifically activate the DREADDs in that region of the brain, 
rather than an I.P. injection which would activate DREADDs wherever they are expressed. CNO treated 
animals significantly reduced binge-like ethanol consumption compared to vehicle treated animals and this 
was analyzed using two-way ANOVA (treatment vs. time) (N=6) [treatment: F(1,5)=21.73, p<0.01; time: 
F(1,5)=1.178, p>0.05; interaction: F(1,5)=0.2375, p>0.05; Total t-test t=4.661 df=5, p<0.01] [Fig. 7a]  
There was a significant decrease in BEC between CNO treatment animals and vehicle treated animals 
expressing Gi-coupled DREADDS in NPY1R+ mPFC cells (N=6) BEC [t=2.571 df=5, p<0.05] [Fig. 7b]. 
There was also no significant change in consumption of 3% sucrose [treatment: F(1,6)=0.1932, p>0.05; 
time: F(1,6)=10.03, p<0.05; interaction: F(1,6)=2.625e-005, p>0.05; Total t-test: t=0.4396 df=6, 
p>0.05][Fig. 7c].  
 To verify that there were no off-target interactions of CNO administration to the mice’s ethanol 
consumption mice were treated with a CON DREADD virus and run through the same procedure previously 
described. CNO was not found to have a significant impact on ethanol consumption in these mice by Two-
way ANOVA analysis (N=7) [treatment: F(1,6)=0.9556, p>0.05; time: F(1,6)=0.1854, p>0.05; interaction: 
F(1,6)=0.09302, p>0.05; Total t-test: t=0.9776 df=6, p>0.05] [Fig. 7d]. The CON DREADD animals also 
did not show a significant change in BEC after an administration of CNO [t=0.3039 df=6, p>0.05][Fig.7e]]. 
The CON DREADD animals also did not show a significant change in intake of 3% sucrose solution after 
an administration of CNO (N=9) [treatment: F(1,8)=1.142, p>0.05; time: F(1,8)=1.032, p>0.05; interaction: 
F(1,8)=0.495, p>0.05; Total t-test t=1.069 df=8 p>0.05] [Fig. 7f]. Mice that did not show expression of 
DREADD receptor in the BLA (fluoresce red) were excluded from the study [Fig. 7g] 
Discussion 
In the characteristics of addiction presented by previous research, it has been noted that there are 
certain physiological changes that take place in the brain after chronic exposure to alcohol (Volkow, N. D., 
Koob, G. F., & McLellan, A. T. 2016). In people, some of these changes after chronic alcohol exposure 
include cortical atrophy, abnormalities in mPFC functioning, and overall impairment of the mPFC’s role in 
decision making (Kim MJ. 2011; Seo, S., Beck et al .2018). Along with this, the evidence of overexpressing 
NPY leading to an increase in ethanol intake highlighted NPY as a possible important factor in the binge-
like ethanol intake cycle (Thiele TE, Palmiter RD. 1998). This study has provided evidence that NPY 
signaling in the mPFC has the capability to modulate binge-like ethanol consumption. The IHC experiments 
suggests that NPY is activated by binge-like ethanol intake and with repetitive binge-like ethanol 
consumption, there is a reduction of NPY signaling within the mPFC. Another interesting finding was that 
for the PL region of the mPFC, the decrease in NPY immunoreactivity were seen to correlate with the 
amount of ethanol consumed while it did not correlate for the IL region. This result provides evidence that 
the goal-orientated region of the mPFC, the PL region, is more likely to experience more direct 
physiological changes in the early stages of binge-like drinking behavior. An early change in the goal-
 directed region of the mPFC supports the concept that the early stages of binge-like drinking are more 
directly regulated by a goal-direction rather than habitual direction (Barker, J. M., Taylor, J. R., & Chandler, 
L. J. 2014).  
In our pharmacological experiments, administration of a NPY1R agonist or a NPY2R antagonist 
both reduced binge-like ethanol drinking in mice without significantly impacting sucrose intake, anxiety-
like behavior, or general locomotor behavior. This observation of NPY signaling affecting binge-like 
ethanol intake was paralleled by the chemogenetic studies. Since NPY has been shown to act as an 
inhibitory transmitter on Gi-coupled receptors, the use of DREADD technology in NPY1R-cre mice 
provides a means to chemogenetically silence NPY1R+ cells in the mPFC. When the mPFC NPY1R+ cells 
were chemogenetically silenced, there was a decrease in ethanol consumption. Furthermore, when the 
mPFC NPY1R+ projections to the BLA were chemogenetically silenced the same decrease in binge-like 
ethanol consumption was observed, validating the idea that NPY in the mPFC is able to modulate ethanol 
intake through top-down regulation of the amygdala. While the administration of CNO to Gi-DREADD 
animals decreased ethanol consumption, administration of CNO to CON-DREADD animals did not 
decrease binge-like ethanol consumption in mice compared to vehicle treated mice. This demonstrated that 
there were no significant off-target effects of the CNO administration in the experiments. 
In the pharmacological analysis of the NPY system, the introduction of a NPY1R agonist showed 
a decrease in the mice’s overall ethanol intake compared to vehicle treated mice. The agonist acted as an 
activator of NPY1R, one of NPY’s primary post-synaptic receptor, which has been shown to induce an 
inhibitory signal in the postsynaptic neuron (Sparrow AM. 2012). The administration of a NPY2R 
antagonist, once again decreased overall intake of ethanol compared to vehicle treated mice. The 
introduction of the NPY2R antagonist was expected to decrease the activity of the presynaptic receptor, 
thus increasing further NPY release into the synapse (Robinson, Stacey L., & Thiele, Todd E. 2017). 
Blocking this receptor, should therefore increase endogenous NPY levels in the synapse, which would then 
activate NPY1R. The method of chemogenetically inhibiting the NPY1R+ cells was a way to specifically 
modulate the cell population that would normally be acted on by NPY. The chemogenetic inhibition of cells 
 in the mPFC in general and then specifically mPFC cells projecting to the BLA, both showed decreased 
binge-like ethanol consumption.  
The lack of change in sucrose consumption in both the pharmacological and chemogenetic studies 
showed that the changes to NPY signaling was for ethanol consumption and not all reward-related behavior. 
However, it is possible that this pathway may play a role in other substances of abuse, but further analysis 
would need to be made to examine that claim. The lack of change in locomotor activity of the mice after 
treatment with the NPY1R agonist and NPY2R antagonist was also of note to verify that the change in 
ethanol consumption was not due to the mice’s decreased overall activity. This showed that the mice did 
not drink less because they were lethargic due to the dose administered. Furthermore, the lack of change in 
anxiety-like behavior showed that the dose administered of the drug did not alter other behavioral aspects 
of the mice. However, since a dose-response curve was not made for the drugs used, then there is no proof 
that at a higher dose there may be changes in locomotor and anxiety-like behavior. In the future, a study 
examining the effects of Leu Pro-NPY and BIIE0246 at multiple doses could verify the results observed in 
this experiment. Also, this study has used methods to increase the NPY signaling pathway, in the future 
methods to inhibit the NPY signaling process could be observed to see if there is a reduction in binge-like 
ethanol consumption. This could be done by the use of an NPY1R antagonist or a NPY2R agonist.  
Since NPY1R is expressed in excitatory glutamatergic cells and inhibitory GABAergic 
interneurons in the mPFC, both were targeted by the pharmacological and chemogenetic approaches. A 
further study that would individually target each of these cell populations is still required to parse out the 
role of each of these groups in the top-down regulation of the amygdala. The experiment where CNO was 
administered directly to the BLA in DREADD expressing mice showed that the excitatory glutamatergic 
projections of the mPFC play a role in the mPFC’s regulation of binge-like ethanol consumption. However, 
the role of the mPFC neurons in the regulation of the amygdala should still be further evaluated. Also, while 
the mPFC cells that expressed NPY1R were targeted and shown to have projections to the BLA, there are 
also likely mPFC neurons that express NPY1R that have projections to other parts of the brain. These 
projections could also play a role in the binge-like drinking behavior and projects identifying and analyzing 
 the role of these other regions could provide a more comprehensive picture of the mPFC’s ability to 
modulate ethanol consumption. 
In conclusion, this study has shown the importance of one of the molecular players in the 
development of alcohol addiction. Studying some of the biological factors that contribute to the 
development of addiction build a further understanding of the cyclic pattern of addiction and how the brain 
changes with continual ethanol exposure. The role of NPY in the top down regulation of the amygdala is 
only one of the pieces that is involved in the ethanol dependence. However, this work has shown that the 
release of NPY in the mPFC could be a powerful target for modulation of ethanol intake in people. The use 
of specific targets for the release of NPY in the mPFC could provide another means of attempting to reduce 
ethanol intake in the early stages of binge-like drinking behavior. With continued effort in discovering more 
of the mechanisms in the development of ethanol dependence, more effective treatments can be created to 
combat this debilitating disease. 
  
 
 
Corresponding Authors: 
Stacey Robinson and Todd E. Thiele, Ph.D. 
Department of Psychology & Neuroscience 
University of North Carolina 
Davie Hall, CB# 3270 
Chapel Hill, NC 27599-3270, USA 
 
 
Funding: 
This work was supported by National Institutes of Health grants AA022048, AA013573, AA015148, 
F32AA025811. 
 
 References: 
1. Kanny, D., Liu, Y., Brewer, R. D., Garvin, W. S., & Balluz, L. Vital Signs: Binge Drinking Prevalence, 
Frequency, and Intensity Among Adults-United States, 2010 (Reprinted from MMWR, vol 61, pg 14-
19, 2012). Jama-Journal of the American Medical Association, 307(9), 908-910. 
2. Drinking Levels Defined | National Institute on Alcohol Abuse and Alcoholism (NIAAA). 
Niaaa.nih.gov. Retrieved 26 April 2016, from http://www.niaaa.nih.gov/alcohol-health/overview-
alcohol-consumption/moderate-binge-drinking 
3. Koob, George Fv. The dark side of emotion: The addiction perspective. EUROPEAN JOURNAL OF 
PHARMACOLOGY, 2015;753, 73-87. Robert D Rogers,Narender 
4. Volkow, N. D., Koob, G. F., & McLellan, A. T. Neurobiologic advances from the brain disease model 
of addiction. The New England Journal of Medicine. 2016; 374(4), 363–371. 
5. Frone, Michael R. Work. Stress and Alcohol Use: Developing and Testing a Biphasic Self-Medication 
Model. WORK AND STRESS. 2016; 30(4), 374-394. 
6. Lalumiere RT. Optogenetic dissection of amygdala functioning. Front Behav Neurosci. 2014; 8.107. 
7. Pleil KE, Lowery-Gionta EG, Crowley NA, Li C, Marcinkiewcz CA, Rose JH, et al. Effects of chronic 
ethanol exposure on neuronal function in the prefrontal cortex and extended amygdala. 
Neuropharmacology. 2015;99:735-49. doi:10.1016/j.neuropharm.2015.06.017 
8. Ramnani,Clare Mackay,James L Wilson,Peter Jezzard,Cameron S Carter,Stephen M Smith. Distinct 
portions of anterior cingulate cortex and medial prefrontal cortex are activated by reward processing 
in separable phases of decision-making cognition. Biological Psychiatry. 2004; 55(6), 594-602. 
9. Carballedo A, Scheuerecker J, Meisenzahl E, Schoepf V, Bokde A, Möller HJ, et al. Functional 
connectivity of emotional processing in depression. J Affect Disord. 2011; 134:272-279. 
10. Vertes RP. Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse. 2004; 
51:32-58. 
 11. Barker, J. M., Taylor, J. R., & Chandler, L. J. A unifying model of the role of the infralimbic cortex 
in extinction and habits. Learning & Memory. 2014; 21(9), 441–448. 
http://doi.org/10.1101/lm.035501.114 
12. Kubota Y, Shigematsu N, Karube F, Sekigawa A, Kato S, Yamaguchi N, et al. Selective coexpression 
of multiple chemical markers defines discrete populations of neocortical GABAergic neurons. Cereb 
Cortex. 2011;21:1803-1817. 
13. Allen, Y. S., Bloom, S. R., & Polak, J. M. The neuropeptide Y-immunoreactive neuronal system: 
discovery, anatomy and involvement in neurodegenerative disease. Hum Neurobiol, 1986; 5(4), 227-
234. 
14. Robinson, Stacey L., & Thiele, Todd E. The Role of Neuropeptide Y (NPY) in Alcohol and Drug 
Abuse Disorders. ROLE OF NEUROPEPTIDES IN ADDICTION AND DISORDERS OF 
EXCESSIVE CONSUMPTION. 2017;136, 177-197. 
15. Perlman SB, Almeida JR, Kronhaus DM, Versace A, Labarbara EJ, Klein CR, et al. Amygdala activity 
and prefrontal cortex-amygdala effective connectivity to emerging emotional faces distinguish 
remitted and depressed mood states in bipolar disorder. Bipolar Disord. 2012; 14:162-174. 
16. Sparrow AM, Lowery-Gionta EG, Pleil KE, Li C, Sparrow GM, Cox BR, et al. Central neuropeptide 
Y modulates binge-like ethanol drinking in C57BL/6J mice via Y1 and Y2 receptors. 
Neuropsychopharmacology. 2012;37(6):1409-21. doi:10.1038/npp.2011.327 
17. Palmiter RD, Erickson JC, Hollopeter G, Baraban SC, Schwartz MW. Life without neuropeptide Y. 
Recent Prog Horm Res. 1998;53:163-99. 
18. Thiele TE, Marsh DJ, Ste Marie L, Bernstein IL, Palmiter RD. Ethanol consumption and resistance 
are inversely related to neuropeptide Y levels. Nature. 1998; 396:366–9.10.1038/24614 
19. Thiele TE, Crabbe JC, Boehm SL. "Drinking in the Dark" (DID): a simple mouse model of binge-like 
alcohol intake. Curr Protoc Neurosci. 2012; 68:9.49.41-12. 
20. Sparrow GM, Thiele TE. The neurobiology of binge-like ethanol drinking: evidence from rodent 
models. Physiol Behav. 2012; 106:325-331. 
 21. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like 
behaviors: a review. Eur J Pharmacol. 2003; 463:3-33. 
22. Anthony N. van den Pol. Neuropeptide transmission in brain circuits. Neuron. 2012;76(1):98-115.) 
23. Kim MJ, Gee DG, Loucks RA, Davis FC, Whalen PJ. Anxiety dissociates dorsal and ventral medial 
prefrontal cortex functional connectivity with the amygdala at rest. Cereb Cortex. 2011;21(7):1667-
73. doi:10.1093/cercor/bhq237 
24. Seo, S., Beck, A, Obermayer, K. et al. Risk profiles for heavy drinking in adolescence: differential 
effects of gender. Addiction Biology, 2018; doi: 10.1111/adb.12636. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figures 
 
Figure 1. NPY Immunoreactivity decreased in the PL of the mPFC after 3 cycles of DID 
A) Timeline of the 3 cycles of DID ethanol or water exposure the mice went through until brain extraction. 
B) Mice that went under 3 cycles of DID showed a decrease in NPY immunoreactivity in both the PL and 
IL of the mPFC compared to water exposed animals. C) Exemplar images of NPY IHC in the PL and IL in 
each treatment group. D) NPY immunoreactivity and total binge-like ethanol consumption on the final day 
of cycle 3 was found to be significantly correlated in the PL. E) NPY immunoreactivity and total binge-like 
 ethanol consumption on the final day of cycle 3 was not found to be significantly correlated in the IL. F) 
NPY immunoreactivity and total water consumption on the final day of cycle 3 did not correlate in the PL. 
G) NPY immunoreactivity and total water consumption on the final day of cycle 3 did not correlate in the 
IL.(* = main factor: liquid p<0.05) (scale bar = 100µm). 
 
 
 
Figure 2: Pharmacological activation of NPY1R in the mPFC significantly reduced binge-like ethanol 
intake without altering sucrose intake. 
A) Timeline of the mice’s 3 cycles of DID ethanol or water exposure with treatment times and tail blood 
collections, followed by the mice’s sucrose trials. B) Administration of NPY1R agonist Leu, Pro-NPY into 
the mPFC significantly reduced ethanol intake over a 2-hour trial period. C)  NPY1R agonist Leu, Pro-
NPY treated animals showed a significant decrease in BEC compared to the vehicle treated animals.  D) 
 The NPY1R agonist Leu, Pro-NPY treated animals did not alter sucrose (3%) intake compared to vehicle 
treated animals. E) Cannulae placement checks with each mark representing a single animal (x = 
misplacement; • = hit). (** = main treatment effect p<0.01; + = posthoc effect p<0.05; # = paired t-test 
p<0.05; ## = paired t-test p<0.01). 
 
Figure 3: Pharmacological activation of NPY1R in the mPFC did not significantly alter locomotor activity 
or anxiety-like behavior. 
A) Administration of NPY1R agonist Leu, Pro-NPY did not significantly change locomotion of the mice 
across a 2-hour trial period. B) Administration of NPY1R agonist Leu, Pro-NPY did not affect anxiety like 
behavior in center time test in locomotion chamber.  
 
 
  
Figure 4: Pharmacological inactivation of NPY2R in the mPFC significantly reduced binge-like ethanol 
intake without altering sucrose intake. 
A) Administration of NPY2R antagonist BIIE0246 into the mPFC significantly reduced ethanol intake 
across the 2-hour trial period. B) The NPY2R antagonist BIIE0246 treated animals showed a significant 
decrease in BEC compared to the vehicle treated animals C) The NPY2R antagonist BIIE0246 treated 
 animals did not alter sucrose (3%) intake compared to vehicle treated animals. D) Cannulae placement 
checks with each mark representing a single animal (x = misplacement; • = hit). (* = main treatment effect 
p<0.05; ++ = posthoc effect p<0.01; # = paired t-test p<0.05). 
 
 
 
 
Figure 5. Pharmacological inactivation of NPY1R in the mPFC did not significantly alter locomotor 
activity or anxiety-like behavior. 
A) Administration of NPY2R antagonist BIIE0246 into the mPFC through a cannulae significantly reduce 
ethanol intake across the 2-hour trial period [Two-way ANOVA: time = F(23,299)=26.97, p<0.0001; 
treatment = F(1,13)=0.2791, p>0.05; interaction: F(23,299)=0.7306, p>0.05; Vehicle N=10, BIIE0246 
N=5]. B) The NPY2R antagonist BIIE0246 treated animals did not alter sucrose (3%) intake compared to 
vehicle treated animals (p>0.05, N=9). C) The NPY2R antagonist BIIE0246 treated animals the showed a 
non-significant decreased in BEC compared to the vehicle treated animals (t=0.5788 df=13, p>0.05; 
Vehicle N=10; BIIE0246 N=5). 
 
  
 
 
Figure 6. Chemogenetic inhibition of mPFC NPY1R+ neurons reduced binge-like ethanol intake without 
altering sucrose intake. 
 A) Administration of CNO via IP injection significantly reduced ethanol intake in NPY1R+ neurons in the 
mPFC expressing Gi-DREADD.  B) CNO administration did not significantly reduce BEC relative to 
vehicle treated animals. C) CNO administration did not alter sucrose intake compared to vehicle treated 
animals. D) CNO administration did not significantly change ethanol intake for CON DREADD animals. 
E) CNO administration did not significantly change sucrose intake for CON DREADD animals.  F) 
Exemplar image of Gi-DREADD expression in the mPFC. (* = main treatment effect p<0.05; # = paired t-
test p<0.05). 
  
 
 
Figure 7. Chemogenetic inhibition of mPFC to BLA NPY1R+ neurons significantly reduced binge-like 
ethanol intake without altering sucrose intake.  
A) Administration of CNO via IP injection significantly reduced ethanol intake for mice with NPY1R+ 
neurons in the mPFC projecting to the BLA expressing Gi-DREADD. B) CNO administration significantly 
reduced BEC relative to vehicle treated animals. C) CNO administration did not significantly change 
sucrose intake in Gi-DREADD animals. D) Administration of CNO did not significantly reduce ethanol 
intake for mice with NPY1R+ neurons in the mPFC projecting to the BLA expressing CON DREADD. E) 
CNO administration did not significantly change BEC in CON DREADD animals. F) CNO administration 
did not significantly change sucrose intake in CON DREADD animals. G) TOP: Cannulae placement 
checks with each mark representing a single cannulae (2 per animal) (x = misplacement; • = hit); BOTTOM: 
exemplar image of mPFC NPY1R+ terminal fluorescence in the BLA of a NPY1R-cre mouse (scale bar = 
250µm). (** = main treatment effect p<0.01; # = paired t-test p<0.05; ## = paired t-test p<0.01) 
